Tian J, Fu W, Xie Z, Zhao Y, Yang H, Zhao J
Proteome Sci. 2024; 22(1):2.
PMID: 38245706
PMC: 10799539.
DOI: 10.1186/s12953-024-00228-x.
Kavukcu S, Ensarioglu H, Karabiyik H, Vatansever H, Turkmen H
ACS Omega. 2023; 8(40):37549-37563.
PMID: 37841164
PMC: 10569012.
DOI: 10.1021/acsomega.3c05898.
Durig J, Calcagni M, Buschmann J
Mater Today Bio. 2023; 22:100757.
PMID: 37593220
PMC: 10430620.
DOI: 10.1016/j.mtbio.2023.100757.
Liu C, Li S, Tang Y
Cancer Chemother Pharmacol. 2023; 92(5):329-340.
PMID: 37535106
DOI: 10.1007/s00280-023-04572-1.
Shah A, Surnar B, Kolishetti N, Dhar S
Acc Mater Res. 2023; 3(3):283-296.
PMID: 37091880
PMC: 10117633.
DOI: 10.1021/accountsmr.1c00178.
Anticancer Platinum Drugs Update.
Ciarimboli G
Biomolecules. 2021; 11(11).
PMID: 34827636
PMC: 8615753.
DOI: 10.3390/biom11111637.
Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy.
Zhu L, Wang Y, Lv W, Wu X, Sheng H, He C
Int J Mol Med. 2021; 48(6).
PMID: 34643254
PMC: 8522958.
DOI: 10.3892/ijmm.2021.5047.
Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study.
Hu X, Chen X, Li T, Liu Z, Guo X, Ouyang Z
Cancer Manag Res. 2021; 13:1491-1503.
PMID: 33623429
PMC: 7894794.
DOI: 10.2147/CMAR.S294677.
Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles.
Mokesch S, Cseh K, Geisler H, Hejl M, Klose M, Roller A
Front Chem. 2020; 8:209.
PMID: 32318543
PMC: 7147246.
DOI: 10.3389/fchem.2020.00209.
Cisplatin-Based Chemotherapy of Human Cancers.
Brown A, Kumar S, Tchounwou P
J Cancer Sci Ther. 2020; 11(4).
PMID: 32148661
PMC: 7059781.
A Proteomic View of Cellular Responses to Anticancer Quinoline-Copper Complexes.
Dalzon B, Bons J, Diemer H, Collin-Faure V, Marie-Desvergne C, Dubosson M
Proteomes. 2019; 7(2).
PMID: 31238524
PMC: 6630412.
DOI: 10.3390/proteomes7020026.
BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.
Rath E, Cheng Y, Pinese M, Sarun K, Hudson A, Weir C
PLoS One. 2018; 13(8):e0203003.
PMID: 30157247
PMC: 6114908.
DOI: 10.1371/journal.pone.0203003.
Poly Organotin Acetates against DNA with Possible Implementation on Human Breast Cancer.
Latsis G, Banti C, Kourkoumelis N, Papatriantafyllopoulou C, Panagiotou N, Tasiopoulos A
Int J Mol Sci. 2018; 19(7).
PMID: 30011935
PMC: 6073380.
DOI: 10.3390/ijms19072055.
Interaction of the New Monofunctional Anticancer Agent Phenanthriplatin With Transporters for Organic Cations.
Hucke A, Park G, Bauer O, Beyer G, Koppen C, Zeeh D
Front Chem. 2018; 6:180.
PMID: 29888219
PMC: 5982655.
DOI: 10.3389/fchem.2018.00180.
Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage.
Pesch T, Schuhwerk H, Wyrsch P, Immel T, Dirks W, Burkle A
BMC Cancer. 2016; 16:469.
PMID: 27412346
PMC: 4944496.
DOI: 10.1186/s12885-016-2538-0.
Potential Compounds for Oral Cancer Treatment: Resveratrol, Nimbolide, Lovastatin, Bortezomib, Vorinostat, Berberine, Pterostilbene, Deguelin, Andrographolide, and Colchicine.
Bundela S, Sharma A, Bisen P
PLoS One. 2015; 10(11):e0141719.
PMID: 26536350
PMC: 4633227.
DOI: 10.1371/journal.pone.0141719.
Ototoxicity in dogs and cats.
Oishi N, Talaska A, Schacht J
Vet Clin North Am Small Anim Pract. 2012; 42(6):1259-71.
PMID: 23122180
PMC: 3490132.
DOI: 10.1016/j.cvsm.2012.08.005.
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
Shen D, Pouliot L, Hall M, Gottesman M
Pharmacol Rev. 2012; 64(3):706-21.
PMID: 22659329
PMC: 3400836.
DOI: 10.1124/pr.111.005637.
In silico approach to cisplatin toxicity. Quantum chemical studies on platinum(II)-cysteine systems.
Chojnacki H, Kuduk-Jaworska J, Jaroszewicz I, Janski J
J Mol Model. 2009; 15(6):659-64.
PMID: 19221812
DOI: 10.1007/s00894-009-0469-2.
Nuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs.
Maldonado Lagunas V, Melendez-Zajgla J
Met Based Drugs. 2008; 2008:576104.
PMID: 18414584
PMC: 2291150.
DOI: 10.1155/2008/576104.